Holen Sie sich die Stockscreener-App
20.50
0.64%
0.13
Handel nachbörslich:
20.50
Schlusskurs vom Vortag:
$20.37
Offen:
$20.41
24-Stunden-Volumen:
13,580
Relative Volume:
0.01
Marktkapitalisierung:
$32.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.35M
KGV:
-14.14
EPS:
-1.45
Netto-Cashflow:
$-36.91M
1W Leistung:
-6.05%
1M Leistung:
-26.23%
6M Leistung:
+502.94%
1J Leistung:
+288.26%
1-Tages-Spanne:
$19.84
$21.36
1-Wochen-Bereich:
$19.42
$23.85
52-Wochen-Spanne:
$2.01
$38.33
Galecto Inc Stock (GLTO) Company Profile
Firmenname
Galecto Inc
Sektor
Branche
Telefon
45-70-70-52-10
Adresse
75 STATE STREET, BOSTON
Vergleichen Sie GLTO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
20.50 | 32.54M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Eingeleitet | Guggenheim | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | BofA Securities | Buy |
| 2020-11-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | SVB Leerink | Outperform |
Galecto Inc Aktie (GLTO) Neueste Nachrichten
What risks investors should watch in Galecto Inc. stock2025 Year in Review & Consistent Growth Equity Picks - ulpravda.ru
Is Galecto Inc. stock attractive for hedge fundsJuly 2025 Breakouts & Daily Price Action Insights - ulpravda.ru
Is Galecto Inc. stock supported by innovation pipeline2025 Risk Factors & Fast Gain Swing Alerts - ulpravda.ru
Should I hold or sell Galecto Inc. stock in 2025July 2025 Patterns & High Conviction Investment Ideas - ulpravda.ru
Galecto (NASDAQ:GLTO) Now Covered by Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Galecto (GLTO) with Outperform Recommendation - Nasdaq
Leerink Partners Initiates Coverage on GLTO with 'Outperform' Ra - GuruFocus
Leerink Partners initiates coverage on Galecto stock with Outperform rating By Investing.com - Investing.com Nigeria
Leerink Partners initiates coverage on Galecto stock with Outperform rating - Investing.com India
Galecto strengthens its leadership after recent acquisition in the US - medwatch.com
Galecto Appoints Sherwin Sattarzadeh as Chief Operating Officer - MarketScreener
Galecto appoints new chief operating officer, enhances leadership - TipRanks
Galecto announces key additions to leadership team - MarketScreener
Galecto appoints Sherwin Sattarzadeh as chief operating officer and issues warrant - Investing.com
Galecto, Inc. Appoints New Chief Operating Officer - TradingView — Track All Markets
Galecto Announces Key Additions to Leadership Team - The Manila Times
Galecto (GLTO) grants large warrant and hires new Chief Operating Officer - Stock Titan
Galecto, Inc. Appoints Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer, Effective January 5, 2026 - MarketScreener
Galecto appoints former Blueprint Medicines executives as COO and CMO - MSN
Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA) - Defense World
Is the Market Bullish or Bearish on Galecto Inc? - Benzinga
Galecto Files to Register 60.5 Million Shares for Secondary Offering - MarketScreener
Galecto (NASDAQ:GLTO) Shares Down 13.3%Time to Sell? - MarketBeat
Galecto (NASDAQ:GLTO) Shares Down 13.3% – Time to Sell? - Defense World
[EFFECT] Galecto, Inc. SEC Filing - Stock Titan
Ideas Watch: Should I hold or sell Galecto Inc stock in 2025 - moha.gov.vn
Why Galecto Inc. stock could benefit from AI revolution2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Galecto (GLTO) Price Target Increased by 12.50% to 36.72 - Nasdaq
How Galecto Inc. stock performs after earningsQuarterly Profit Summary & Reliable Breakout Forecasts - Улправда
How rising interest rates impact Galecto Inc. stock2025 Winners & Losers & Reliable Trade Execution Plans - DonanımHaber
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Galecto, Inc. announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Galecto (NASDAQ:GLTO) Price Target Raised to $36.00 at Guggenheim - Defense World
Guggenheim Maintains Galecto (GLTO) Buy Recommendation - Nasdaq
Guggenheim raises Galecto stock price target to $36 on positive ASH25 data - Investing.com Nigeria
Galecto (GLTO) Rating Maintained by Guggenheim, Price Target Rai - GuruFocus
Galecto (NASDAQ:GLTO) Upgraded to “Hold” at Wall Street Zen - Defense World
Galecto (GLTO) Price Target Increased by 433.33% to 32.64 - Nasdaq
Guggenheim Begins Coverage on Galecto (NASDAQ:GLTO) - Defense World
Galecto, Inc. (GLTO) -5.1% in After-hours: What’s Driving the Move? - Stocks Telegraph
Galecto, Inc. (GLTO) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Galecto (GLTO) Stock Analysis Report | Financials & Insights - Benzinga
Guggenheim Initiates Coverage of Galecto (GLTO) with Buy Recommendation - Nasdaq
Galecto (GLTO) Receives "Buy" Rating from Guggenheim | GLTO Stoc - GuruFocus
Guggenheim Initiates Coverage on Galecto With Buy Rating, $32 Price Target - marketscreener.com
Guggenheim initiates Galecto stock with Buy rating on DMR-001 potential - Investing.com
Guggenheim initiates Galecto stock with Buy rating on DMR-001 potential By Investing.com - Investing.com India
Profit Review: Why Galecto Inc. stock could benefit from AI revolution2025 Key Lessons & Growth Oriented Trading Recommendations - moha.gov.vn
Its Stock Has Paid Off Big Time For Galecto Inc - setenews.com
Mintz Advises Galecto, Inc. in its acquisition of Damora Therapeutics, Inc. and its concurrent $285 million private placement - Mintz
Finanzdaten der Galecto Inc-Aktie (GLTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):